SEC Form 4 · accession 0000880771-17-000056
SCICLONE PHARMACEUTICALS INC · SCLN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Lan Xie
Officer — VP Finance, China CFO
Period of report
Mar 15, 2017
Accepted (ET)
Mar 17, 2017 · 4:50 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000880771
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Mar 15, 2017 | M | 1,000 | $0.00 | A | 1,000 | D | |
| Common Stock | Mar 16, 2017 | S | 1,000 | $9.60 | D | 0 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Restricted Stock UnitF2,F3,F4 | $0.00 | Mar 15, 2017 | M | 1,000 | D | — | Mar 15, 2026 | Common Stock | 1,000 | 19,000 | D |
Explanation of responses
- F1The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 18, 2016.
- F2Granted under the Issuer's 2015 Equity Incentive Plan.
- F3Each restricted stock unit represents the right to receive, at settlement, one share of common stock.
- F4Vesting for such RSUs will occur 25% on March 15, 2017, 25% on March 15, 2018, 25% on March 15, 2019, and 25% on March 15, 2020, contingent upon the executive's continued employment.